MX2021003945A - Compuestos de indolinona para uso como inhibidores de map4k1. - Google Patents

Compuestos de indolinona para uso como inhibidores de map4k1.

Info

Publication number
MX2021003945A
MX2021003945A MX2021003945A MX2021003945A MX2021003945A MX 2021003945 A MX2021003945 A MX 2021003945A MX 2021003945 A MX2021003945 A MX 2021003945A MX 2021003945 A MX2021003945 A MX 2021003945A MX 2021003945 A MX2021003945 A MX 2021003945A
Authority
MX
Mexico
Prior art keywords
sup
compounds
map4k1
inhibitors
indolinone compounds
Prior art date
Application number
MX2021003945A
Other languages
English (en)
Inventor
Laxmikant Atmaram Gharat
Sachin Sundarlal Chaudhari
Prashant Dilip Wadekar
Malini Bajpai
Sachin Vasantrao Dhone
Bharat Gangadhar Adik
Pravin Iyer
Nagaraj Gowda
Original Assignee
Ichnos Sciences S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ichnos Sciences S A filed Critical Ichnos Sciences S A
Publication of MX2021003945A publication Critical patent/MX2021003945A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom

Abstract

La presente descripción se refiere a compuestos de fórmula (I) y sales farmacéuticamente aceptables de los mismos, en donde el anillo A, el anillo C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m y n son como se definen en la presente, que son útiles como inhibidores de MAP4K1, procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos y el uso de los compuestos o las composiciones en el tratamiento o prevención de diversas enfermedades, condiciones y/o trastornos mediados por MAP4K1. (ver Fórmula).
MX2021003945A 2018-10-05 2019-10-07 Compuestos de indolinona para uso como inhibidores de map4k1. MX2021003945A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201821037777 2018-10-05
IN201921009045 2019-03-08
IN201921024673 2019-06-21
PCT/EP2019/077086 WO2020070331A1 (en) 2018-10-05 2019-10-07 Indolinone compounds for use as map4k1 inhibitors

Publications (1)

Publication Number Publication Date
MX2021003945A true MX2021003945A (es) 2021-05-27

Family

ID=68208286

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003945A MX2021003945A (es) 2018-10-05 2019-10-07 Compuestos de indolinona para uso como inhibidores de map4k1.

Country Status (15)

Country Link
US (1) US20230009626A1 (es)
EP (1) EP3860976A1 (es)
JP (1) JP7101311B2 (es)
KR (1) KR20210068479A (es)
CN (1) CN113227049A (es)
AU (1) AU2019352075B2 (es)
BR (1) BR112021006319A2 (es)
CA (1) CA3115000A1 (es)
CL (1) CL2021000844A1 (es)
IL (1) IL281961A (es)
MX (1) MX2021003945A (es)
PE (1) PE20211054A1 (es)
SG (1) SG11202103459WA (es)
WO (2) WO2020070332A1 (es)
ZA (1) ZA202102259B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR20180100425A (el) * 2018-09-19 2020-05-11 Ηλιας Γεωργιου Τσιαβες Περιστρεφομενο κυπελλο μεταφορας για τα μπρατσα των καθρεπτων της μοτοσυκλετας
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
JP7460644B2 (ja) 2018-10-31 2024-04-02 ギリアード サイエンシーズ， インコーポレイテッド Ｈｐｋ１阻害剤としての置換６－アザベンゾイミダゾール化合物
US11453681B2 (en) * 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
TW202321239A (zh) 2021-07-20 2023-06-01 瑞典商阿斯特捷利康公司 作為ｈｐｋ１抑制劑用於治療癌症之經取代的吡𠯤—２—甲醯胺
WO2024017372A1 (zh) * 2022-07-22 2024-01-25 成都百裕制药股份有限公司 一种吲哚酮衍生物及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
AU5468499A (en) * 1998-08-04 2000-02-28 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
UA75054C2 (uk) * 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
DE19949209A1 (de) * 1999-10-13 2001-04-19 Boehringer Ingelheim Pharma In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
AU2002341881B2 (en) * 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US6747025B1 (en) * 2002-11-27 2004-06-08 Allergan, Inc. Kinase inhibitors for the treatment of disease
US8344018B2 (en) * 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
WO2013074459A1 (en) * 2011-11-14 2013-05-23 Ligand Pharmaceuticals, Inc. Methods and compositions associated with the granulocyte colony-stimulating factor receptor
IL292977A (en) * 2016-09-09 2022-07-01 Incyte Corp Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy
US20180228786A1 (en) * 2017-02-15 2018-08-16 Incyte Corporation Pyrazolopyridine compounds and uses thereof

Also Published As

Publication number Publication date
CN113227049A (zh) 2021-08-06
AU2019352075B2 (en) 2022-07-21
CL2021000844A1 (es) 2021-11-12
KR20210068479A (ko) 2021-06-09
ZA202102259B (en) 2022-04-28
WO2020070332A1 (en) 2020-04-09
PE20211054A1 (es) 2021-06-07
EP3860976A1 (en) 2021-08-11
JP2022502455A (ja) 2022-01-11
CA3115000A1 (en) 2020-04-09
SG11202103459WA (en) 2021-05-28
IL281961A (en) 2021-05-31
JP7101311B2 (ja) 2022-07-14
US20230009626A1 (en) 2023-01-12
BR112021006319A2 (pt) 2021-07-06
WO2020070331A1 (en) 2020-04-09
AU2019352075A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
PH12020551821A1 (en) Novel compounds
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PH12018500212A1 (en) 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
NZ765590A (en) Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
TW201612158A (en) Amide derivatives and salts thereof, preparation process and pharmaceutical use thereof
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
PH12020550503A1 (en) Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MD20160105A2 (ro) 2-Amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8H)-il-1,3-tiazol-4-il amide
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2020010949A (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones viricas.
MX2022013273A (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus metodos de uso.
MX2022007518A (es) Derivados bencimidazol.
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MY195576A (en) Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.